In my opinion they will maintain offices in the U.S. and that headquarters will remain stateside. I have no doubts of that.
Nigeria is not a place to base a major manufacturing company out of and remember this and think hard on it. Nigeria, although a huge market is not even 25% of the market for Nicosan. This is going to be an INTERNATIONAL company. It will remain an American company, on an American stock exchange which requires reporting. You cannot discount the importance of 5-HMF which is going to be an American drug. I believe strongly that Virginia Commonwealth University did not license this compound to Xechem with anything else in mind less than FDA approval and commercialization.
Another thing none of you has ever talked about on this board is the fact that there are most likely other applications for Nicosan other than SCD. Many drugs out there which were developed for one indication find it works in other illnesses and disease states. Sometimes those secondary indications once granted by the FDA end up being more profitable than their original application. This possiblity is very real because each of those little pills contain compounds that have beneficial effects on other body systems beside red blood cells. Any good herbalist could take those plants and right off the top of his head tell you what illnesses each of them is used for as well as combinations of the compounds used in additional ailments. Just knowing how Chinese herbs are used I can see where altering the dosage (which wouldn't be difficult considering the lack of toxicity) could open up even further applications. You can do a lot with a pill containing 4 separate healing plant compounds.
There's not a pharmaceutical company out there who has a product to market that hasn't tried to obtain additional indications for their drugs. This one is going to be no exception. The big deal is that a drug that was designed the way this one is inherently has far greater probability for use in other disease states.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.